Metabolic Approaches to Chronic Liver Disease (S9)
January 1-4, 2027
| Location to be Determined
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
Saturday, January 2, 2027
| 8:00–9:00 AM |
Welcome and Keynote Address |
|
| |
Helen H. Hobbs †, University of Texas Southwestern Medical Center
Genetic Determinants of Chronic Liver Disease Progression |
|
| 9:00–11:15 AM |
Role of Intrahepatic Lipid Metabolism in Steatotic Liver Diseases |
|
| |
Jay D. Horton, University of Texas Southwestern Medical Center
Role of Intrahepatic Lipid Metabolism in Steatotic Liver Diseases |
|
| |
Peter A. Crawford †, University of Minnesota
Ketogenesis and Fatty Acid Synthesis |
|
| |
Kathryn E. Wellen †, University of Pennsylvania
New and Surprising Directions in de novo Lipogenesis |
|
| |
Brian N. Finck †, Washington University
Interorgan Communication and Hepatic Lipogenesis |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:15–12:15 PM |
Panel Discussion 1: What will be the Residual Risk if Patients are Placed in Incretin Therapy for Obesity? Then, What is the Residual Risk in MASH? |
|
| 11:15–1:00 PM |
Poster Setup |
|
| 11:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Molecular Drivers of Chronic Liver Disease |
|
| |
Ana Maria Cuervo †, Albert Einstein College of Medicine
Role of Autophagy in Chronic Liver Disease |
|
| |
Peng Li †, Zengzhou University and Tsinghua University
Role of Lipid Droplet Proteins in MASLD |
|
| |
Orian S Shirihai †, David Geffen School of Medicine at UCLA
Mitochondrial Function in Chronic Liver Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Emerging Therapeutic Approaches to Treat Chronic Liver Diseases |
|
| |
Bei B. Zhang, Novo Nordisk
Unraveling Complex Biology and Improving Cardiometabolic Health with New Therapies |
|
| |
Erik Ingelsson †, Wave Life Sciences
Silencing INHBE to Achieve Healthy, Sustainable Weight Loss through Fat Burning, and Muscle Maintenance |
|
| |
Ruth E. Gimeno †, Eli Lilly and Company
Incretin therapies in MASLD |
|
| |
Gerald I. Shulman †, Yale University School of Medicine
Role of Uncouplers in Preventing MASLD Progression and Fibrosis |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–12:00 PM |
Panel Discussion 2: Is Weight Loss Induced Loss in Muscle Mass a Problem? |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Peripheral Organ Contribution and Pathogenesis of Liver Fibrosis |
|
| |
David Brenner †, Sanford Burnham Prebys
Molecular Events Leading to Stellate Cell Activation and Fibrosis in Chronic Liver Disease |
|
| |
Philipp E. Scherer †, University of Texas Southwestern Medical Center
The Role of the Adipocyte in Chronic Liver Disease |
|
| |
Liming Pei †, Children's Hospital of Philadelphia/University of Pennsylvania
Pathogenesis and Mechanisms Underlying Fontan-Associated Liver Disease (FALD) |
|
| |
Sarah Ewald †, University of Virginia
Cachexia and Hepatic Fibrosis |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Weight Loss and Exercise in MASLD Progression |
|
| |
Samuel Klein, Washington University School of Medicine
Metabolic and Hepatic Implications of Weight Loss |
|
| |
Arun J. Sanyal †, Virginia Commonwealth University Medical Center
How Much Weight Loss is Needed to Effectively Impact MASLD and Fibrosis |
|
| |
Juleen R. Zierath †, Karolinska Institutet
Exercise Medicine for MASLD |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Role of Peripheral Organs in Chronic Liver Disease Progression |
|
| |
Caterina Conte †, San Raffaele Roma Open University
Sarcopenia in Obesity and MASLD: Definition and Clinical Implications |
|
| |
Saswata Talukdar †, Merck
Effect of Myostatin and Activin Inhibition on Muscle Mass, Strength and Function |
|
| |
Amalia Gastaldelli †, Institute of Clinical Physiology
Linking Glucose Metabolism to MASLD Progression |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
